The management of patients on therapies is an important part of the lung cancer nurse specialist role. This article focuses on the use of ceritinib in patients with ALK-positive non-small cell lung cancer who have previously been treated with crizotinib, the common toxicities that may arise and how to manage them in order to improve patient experience and adherence to treatment.
Cancer Nursing Practice. 15, 10, 30-33. doi: 10.7748/cnp.2016.e1364cCorrespondence
This article has been subject to external double-blind peer review and checked for plagiarism using automated softwareConflict of interest
This supplement has been commissioned and paid for by Novartis. Novartis has funded medical writing support through Nyxeon Healthcare Communications and payment to the journal for advertorial space. All authors contributed equally to the development, design and review of this article; Novartis has reviewed and approved the content
Received: 30 September 2016
Accepted: 07 November 2016
Alternatively, you can purchase access to this article for the next seven days. Buy now